Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Genus Plc
Director/PDMR Shareholding
Genus plc has announced that Non-Executive Director Celia Baxter purchased 2,336 ordinary shares on 26 June 2026 on the London Stock Exchange for an average price of £21.39512 per share. This transaction, involving a total investment of approximately £49,999.99, represents a direct investment by a director in the company's stock.
Director/PDMR Shareholding
Genus plc announced that Non-Executive Director Celia Baxter purchased 1,728 ordinary shares on 27 February 2026 at an average price of £28.92865 per share on the London Stock Exchange. This transaction, representing a direct investment by a director, could be viewed positively by the market as a sign of confidence in the company's future prospects.
Director/PDMR Shareholding
12 September 2024 Genus plc Director/PDMR Shareholding Genus plc (LSE: GNS) announces that on 11 September 2024, conditional nil-cost share options were granted under the Genus 2019 Performance Share Plan ('PSP') over ordinary shares in Genus to the Executive Directors and members of the Genus Executive Leadership Team ('GELT') as listed in table A below.
Genus plc Preliminary Results for the Year Ended 30 June 2024
STRUCTURALLY STRENGTHENING GENUS IN A CHALLENGING YEAR WEBCAST AVAILABLE AT 7:01AM GMT, 2.01 EST Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2024. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.
In Vitro Culture Alters Cell Lineage Composition and Cellular Metabolism of Bovine Blastocyst
Profiling bovine blastocyst transcriptome at the single-cell level has enabled us to reveal the first cell lineage segregation, during which the inner cell mass (ICM), trophectoderm (TE), and an undefined population of transitional cells were identified.
Genus plc Reports Interim Results for the Six Months Ended 31 December 2023
Genus (LSE:GNS), a leading global animal genetics company, today announces its interim results for the six months ended 31 December 2023. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.
FGF2, LIF, and IGF-1 (FLI) supplementation improves mouse oocyte in vitro maturation via increased glucose metabolism
Chemically defined oocyte maturation media supplemented with FGF2, LIF and IGF-1 (FLI medium) enabled significantly improved oocyte quality in multiple farm animals, yet the molecular mechanisms behind such benefits were poorly defined. Here, we first demonstrated that FLI medium enhanced mouse oocyte quality assessed by blastocyst formation after in vitro fertilization, and implantation and fetal development after embryo transfer.
Editorial: Global excellence in natural products for endocrine disorders
Endocrine disorders encompass a broad spectrum of health challenges, including hormonal imbalances, metabolic syndromes and infertility in humans. It has become a significant health concern globally in recent decades, and limited therapeutic options have made it even more challenging. Therefore, it’s crucial to conduct further research to find more effective and safe therapeutic approaches to treat endocrine disorders.
Genus plc Preliminary Results for the Year Ended 30 June 2023
SOLID PERFORMANCE AND GOOD STRATEGIC PROGRESS WEBCAST AVAILABLE AT 7:01AM GMT, 2.01 EST Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2023. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.
KOunt: a reproducible KEGG orthologue abundance workflow
Accurate and effective sequence annotation is key in interpreting metagenomic sequence data. The KEGG database is a popular reference database that groups proteins into functional orthologs, termed KEGG orthologs (KOs) (Kanehisa et al. 2022). Several tools that identify KO abundance exist with varying aims. FMAP is a functional analysis pipeline that aligns reads to a KEGG filtered UniProt reference database and calculates gene family abundance (Kim et al. 2016).
Stock Market
GOOD FINANCIAL AND STRATEGIC PROGRESS ACHIEVED WEBCAST AVAILABLE AT 7:01AM GMT, 2.01 EST Genus (LSE:GNS), a leading global animal genetics company, today announces its interim results for the six months ended 31 December 2022. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.
Frontiers | Smallholder pig production and genetics Effect of proportion of Modern European ancestry on grower and sow performance of pigs in smallholder systems in Uganda
Brian M. Babigumira1 Johann Sölkner2* Gábor Mészáros2 Maria Wurzinger2 Christina Pfeiffer2, 3 Craig Lewis4 Bernard A. Lukuyu5 Emily A.
Director/PDMR Shareholding
We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms.
Stock Market | BPAS
Continued Strategic Progress in Challenging Markets Webcast Available at 7:01AM BST, 2.01 EDT Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2022. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM BST, 2.01 EDT.
Genus plc (LSE: GNS), a world leading animal genetics company producing superior breeding livestock through genetic improvement, today announced that it will release its preliminary financial results for the full year ended June 30, 2020, and provide a business update on recent corporate developments in its worldwide porcine and bovine genetics businesses, on Tuesday, September 8, 2020.
Genus Plc (GNS) - Financial and Strategic SWOT Analysis Review [Published by Global Data]
Introduction Genus Plc (GNS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Genus Plc (GNS) - Financial and Strategic SWOT Analysis Review [Report Updated: 10-10-2018]
Introduction Genus Plc (GNS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Genus
Contact Genus, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack